Wouters L, Amery W, Towse G
J Laryngol Otol. 1983 Aug;97(8):697-704. doi: 10.1017/s0022215100094858.
Experience with flunarizine, a selective calcium-entry blocker, in the treatment of dizziness is reviewed. Clinical efficacy was predicted in pharmacological studies both in rabbits and humans: torsion swing or caloric induced nystagmus were significantly suppressed by flunarizine. Open therapeutic findings, using clinical and electronystagmographic or audiographic assessments as well, showed that flunarizine is of benefit to patients with vertigo of labyrinthine as well as of cerebrovascular origin. These results were confirmed in double-blind controlled trials. Flunarizine, either started with a loading dose gradually decreased thereafter, or given at a fixed 10 mg. dose schedule was proven to produce rapid improvement of dizziness and unsteadiness and to be tolerated very well.
本文综述了选择性钙通道阻滞剂氟桂利嗪治疗头晕的经验。在兔和人的药理学研究中预测了其临床疗效：氟桂利嗪可显著抑制扭转摆动或冷热诱发的眼球震颤。采用临床、眼震电图或听力图评估的开放性治疗结果表明，氟桂利嗪对迷路性和脑血管性眩晕患者有益。这些结果在双盲对照试验中得到了证实。氟桂利嗪无论是开始时给予负荷剂量，随后逐渐减量，还是按固定的10毫克剂量给药方案，都被证明能迅速改善头晕和不稳症状，且耐受性良好。
